Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetic cardiomyopathy.

Gregg C Fonarow1, Preethi Srikanthan

  • 1Ahmanson-UCLA Cardiomyopathy Center, UCLA Division of Cardiology, David Geffen School of Medicine at UCLA, 10833 Leconte Avenue, Room BH407, Los Angeles, CA 90095, USA. gfonaarow@mednet.uca.edu

Endocrinology and Metabolism Clinics of North America
|September 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A risk score for in-hospital death in patients admitted with ischemic or hemorrhagic stroke.

Journal of the American Heart Association·2013
Same author

American Heart Association Guide for Improving Cardiovascular Health at the Community Level, 2013 update: a scientific statement for public health practitioners, healthcare providers, and health policy makers.

Circulation·2013
Same author

Ultrafiltration in heart failure with cardiorenal syndrome.

The New England journal of medicine·2013
Same author

Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction.

The American journal of medicine·2013
Same author

Renin-Angiotensin system antagonists and mortality in patients with heart failure.

JAMA·2013
Same author

Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure.

The American journal of medicine·2013

Diabetic cardiomyopathy increases heart failure risk in diabetic patients. This review covers pathogenesis and treatment, emphasizing applying proven therapies to all heart failure patients with diabetes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pathophysiology

Background:

  • Diabetes mellitus significantly elevates the risk of developing heart failure.
  • Comorbid heart failure in diabetic patients leads to increased morbidity and mortality.
  • Diabetic cardiomyopathy represents a distinct cardiac complication of diabetes.

Purpose of the Study:

  • To review recent advances in understanding the pathogenesis of diabetic cardiomyopathy.
  • To discuss current and emerging treatment strategies for diabetic cardiomyopathy.
  • To highlight the importance of applying established heart failure therapies in diabetic patients.

Main Methods:

  • Literature review of recent studies on diabetic cardiomyopathy.
  • Analysis of current guidelines for heart failure management.

Related Experiment Videos

  • Synthesis of information on pathophysiological mechanisms and therapeutic interventions.

    • Main Results:

    • Diabetic cardiomyopathy involves complex mechanisms including metabolic dysfunction, inflammation, and fibrosis.
    • Emerging therapies target specific pathways involved in diabetic heart disease.
    • Standard heart failure treatments are beneficial but require careful application in diabetic populations.

    Conclusions:

    • Understanding diabetic cardiomyopathy pathogenesis is crucial for effective treatment.
    • Integrated management combining glycemic control and heart failure therapies is essential.
    • Prompt application of evidence-based therapies can improve outcomes for heart failure patients with diabetes.